KSH01-TCR-T

KSH01-TCR-T is an investigational autologous T cell therapy in which a patient's own CD4+ and/or CD8+ T cells are genetically engineered using a lentiviral vector to express a T cell receptor (TCR) specifically targeting the tumor-associated antigen **MAGE-A4 (Melanoma-associated antigen 4)**. Upon reinfusion, these engineered T cells recognize and bind to MAGE-A4-expressing tumor cells, inducing cell death through antigen-specific cytotoxicity. This therapy is being developed primarily for the treatment of refractory or relapsed solid tumors, including bladder cancer, esophageal carcinoma, gastrointestinal cancers, melanoma, head and neck cancer, and sarcoma[1][3][5][8][9]. Primary mechanism: adoptive cell therapy using engineered, antigen-specific TCR-T cells. Developer: TCRx Therapeutics / Keshihua (Nanjing) Biotechnology Key features: Early-stage clinical trials in China, targeting patients with advanced malignant solid tumors with positive MAGE-A4 expression, eligibility requires HLA-A*02 positivity, autologous PBMC collection, and ex vivo expansion and genetic modification of patient T cells before reinfusion[5][7][9].

Brand names

KSH01-TCR-TKSH-01-TCR-TKSH 01-TCR-T

Other names

autologous engineered TCR-T cells KSH01autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against MAGE-A4 antigen